BiotechTube

Azeliragon + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Jun 27, 2019 → Jan 29, 2021

NCT ID
NCT03980730

About Azeliragon + Placebo

Azeliragon + Placebo is a phase 2 stage product being developed by vTv Therapeutics for Alzheimer Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03980730. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03980730Phase 2Terminated
NCT02080364Phase 3Terminated

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from vTv Therapeutics

Azeliragon + PlaceboPhase 3
69
Azeliragon 5mgPhase 3
69
Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + PlaceboPhase 3
69
TTP054 + PlaceboPhase 2
44
TTP399 400 mg + TTP399 800 mg + Sitagliptin 100 mg + PlaceboPhase 2
44